VERTEX PHARMACEUTICALS INC financial statements, including revenue, expenses, profit, and loss
The total revenue of VX1 for the last quarter is 2.42 B CHF, and it's 14.23% higher compared to the previous quarter. The net income of Q1 24 is 991.97 M CHF.